Prickly pear (Opuntia ficus-indica) is increasingly studied for its antioxidant and anti-inflammatory properties. The extract in NeuroSalt is standardized at a 20:1 concentration ratio, meaning it's ...

Join the Grand Opening Celebration on May 1, 2026, for an Evening of Beauty and Innovation ...

As consumer attention around transdermal wellness patches grows in 2026, interest has also expanded around ingredient visibility, product variety, and policy transparency across the category. This ...

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, ...

CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and ...

Alameda, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Checkerspot, a biotechnology company pioneering the development of bioactive lipids from microalgae, today introduced Algolein™, a new line of ...

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete ...

Goldman Sachs & Co. LLC, Jefferies, and William Blair are acting as joint lead bookrunning managers for the proposed offering. BofA Securities and Evercore ISI are acting as bookrunning managers for ...

Collaboration marks the first clinical pilot of AI-assisted MRI analysis for endometriosis.

ORLANDO, Fla., April 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference.

Notably, the FDA has agreed to integrate safety data from both AD and PD populations from the Company’s completed and ongoing clinical trials in the NDA for AD, enabling regulatory efficiency that is ...